I kappa B kinase (IKK) complex plays an important role in the regulation of signaling pathway that activates nuclear factor-kappa-B (NF-jB). Recently, we reported that cisplatin (CDDP) treatment causes a remarkable nuclear accumulation of IKK-a in association with stabilization and activation of p73. However, underlying mechanisms of CDDP-induced nuclear accumulation of IKK-a are elusive. Here, we found that ataxia-telangiectasia mutated (ATM) is one of upstream mediators of IKK-a during CDDP-induced apoptosis. In response to CDDP, ATM was phosphorylated at Ser-1981, which was accompanied with nuclear accumulation of IKK-a in HepG2 cells, whereas CDDP treatment had undetectable effects on IKK-a in ATM-deficient cells. Indirect immunofluorescence experiments demonstrated that phosphorylated form of ATM colocalizes with nuclear IKK-a in response to CDDP. In vitro kinase assay indicated that ATM phosphorylates IKK-a at Ser-473. Moreover, IKKa-deficient MEFs displayed CDDP-resistant phenotype as compared with wild-type MEFs. Taken together, our present results suggest that ATM-mediated phosphorylation of nuclear IKK-a, which stabilizes p73, is one of the main apoptotic pathways in response to CDDP.
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A wide variety of extracellular stimuli triggers activation of IKK complex, which phosphorylates IkB and induces its rapid degradation in an ubiquitin/proteasomedependent manner. NF-kB is then translocated into nucleus, where transcription of its target genes is induced (Karin and Ben-Neriah, 2000) . Despite structural similarity between IKK-a and IKK-b, IKK-a knockout mice displayed distinct phenotypes from those of IKK-b-deficient mice (Hu et al., 1999; Li et al., 1999a, b; Takeda et al., 1999) . IKK-a-deficient mice exhibited various morphological abnormalities including defective epidermal differentiation; however, cytokine-induced activation of NF-kB was not severely impaired. In contrast, knockout of IKK-b resulted in embryonic lethality, liver degeneration and inhibition of NF-kB activation. In support with these results, IKK-b has an extremely higher activity toward IkB than IKK-a (Huynh et al., 2000) . Thus, IKK-b has been considered to be an essential signal transducer in NF-kB activation (Li et al., 1999) . Current studies demonstrated that IKK complex undergoes changes in subcellular distribution, suggesting that IKK complex has a novel nuclear function. In contrast to IKK-b, IKK-a accumulated in cell nucleus in response to cytokine exposure and was directly recruited onto the promoter of NF-kB-regulated genes in association with histone H3 phosphorylation (Anest et al., 2003; Yamamoto et al., 2003) . Additionally, Verma et al. (2004) described that IKK-g shuttles between cytoplasm and nucleus, and interacts with nuclear co-activator CBP. Wu et al. (2006) demonstrated that, upon DNA damage, IKK-g is phosphorylated by ATM, which encodes a PI3 K family of nuclear Ser/Thr kinase (Kastan and Lim, 2000) , and thereby promotes its nuclear export. Recently, we have reported that DNA damage induces nuclear accumulation of IKK-a and nuclear IKK-a stabilizes tumor suppressor p73 (Furuya et al., 2007) . However, precise molecular mechanisms behind DNA damage-induced nuclear accumulation of IKK-a have been unclear. In this study, we found that ATM is one of the upstream mediators of nuclear IKK-a in response to DNA damage.
To examine a possible contribution of ATM to DNA damage-induced accumulation of IKK-a, human hepatocellular carcinoma HepG2 cells were exposed to CDDP. As shown in Figure 1a , HepG2 cells underwent apoptosis in response to CDDP. Immunoblot analysis demonstrated that ATM remains unchanged regardless of CDDP treatment, whereas phospho-ATM increases in response to CDDP (Figure 1b) . Consistent with our recent observations (Furuya et al., 2007) , CDDP treatment resulted in an accumulation of IKK-a as well as p73a, whereas it had undetectable effects on IKK-a and p73a mRNAs ( Figure 1c ). Similar results were also obtained in p53-deficient human lung carcinoma H1299 cells (Supplementary Figure S1 ). As described (Saito et al., 2002; Kurz et al., 2004) , CDDP-induced phosphorylation of ATM and p53 was significantly blocked by wortmannin (Figure 2a ). Of note, wortmannin treatment led to a remarkable inhibition of CDDPdependent accumulation of IKK-a and p73a. Expectedly, CDDP-induced nuclear accumulation of IKK-a was strongly blocked in cells exposed to wortmannin (Figure 2b ), suggesting that ATM might act as one of the upstream mediators of IKK-a in response to DNA damage. In support with this notion, CDDP treatment had negligible effects on IKK-a and p73a in ATMdeficient A-T cells (Figure 2c ). IKK-a and p73a mRNAs remained unchanged in A-T cells treated with CDDP ( Figure 2d ). Additionally, enforced expression of ATM resulted in an induction of nuclear IKK-a (Supplementary Figure S2 ).
Since cytoplasmic IKK-a remained constant in HepG2 cells exposed to CDDP, CDDP-induced nuclear translocation of IKK-a might not occur. To address whether IKK-a could be regulated in a proteasomedependent manner, human osteosarcoma U2OS cells were treated with proteasome inhibitor MG-132 and then analysed for IKK-a. Immunoblot of p53 was performed as a positive control. As shown in Figure 3a , MG-132 treatment caused a significant accumulation of IKK-a. Similar results were also obtained in U2OS cells treated with lactacystin (data not shown). Next, U2OS cells were exposed to MG-132 and fractionated into nuclear and cytoplasmic fractions followed by immunoblotting. As seen in Figure 3b , nuclear and cytoplasmic IKK-a were stabilized by MG-132. To examine whether IKK-a could be regulated by ubiquitin/proteasome system, U2OS cells were co-transfected with IKK-a expression plasmid together with His-tagged ubiquitin. Twenty-four hours after transfection, cells were treated with CDDP for 24 h or left untreated followed by an , total RNA from HepG2 cells was subjected to RT-PCR using the indicated primers. GAPDH was used as an internal control. PCR products were resolved in 2% agarose gels and visualized by ethidium bromide staining.
exposure to MG-132 for 6 h, and ubiquitinated materials were recovered by nickel agarose and then analysed by immunoblotting. As shown in Figure 3c , ubiquitinated forms of IKK-a were detectable under normal conditions, whereas they were significantly reduced in cells exposed to CDDP. Taken together, our results suggest that CDDP treatment stabilizes nuclear IKK-a by blocking ubiquitin/proteasome-dependent degradation system. To investigate whether there could exist a functional interaction between IKK-a and ATM, we examined their subcellular localization. U2OS cells were transfected with FLAG-IKK-a expression plasmid. Thirtysix hours after the transfection, cells were treated with CDDP for 12 h or left untreated and simultaneously stained with anti-phospho-ATM and anti-FLAG antibodies. As shown in Figure 4a , phospho-ATM became detectable in nucleus in response to CDDP. FLAG-IKK-a was largely expressed in cytoplasm without CDDP, whereas CDDP treatment led to an accumulation of FLAG-IKK-a in nucleus. Merged images indicated nuclear colocalization of phospho-ATM and FLAG-IKK-a. Immunoprecipitation experiments indicated that the endogenous ATM forms a complex with IKK-a in cells (Supplementary Figure S3) . Next, we investigated whether ATM could phosphorylate IKK-a. As described (Kastan and Lim, 2000) , ATM phosphorylates Ser/Thr followed by Glu. According to our extensive search of the amino acid residues of IKK-a, we found six putative ATM-dependent phosphorylation sites (Figure 4b ). In vitro kinase assay using anti-ATM immunoprecipitates from HeLa cells exposed to CDDP revealed that GST-IKK-a (335-745) but not GST-IKK-a (2-334) is phosphorylated by anti-ATM ATM-mediated accumulation of nuclear IKK-a K Yoshida et al immunoprecipitates (data not shown). Thus, we focused on GST-IKK-a (335-745) and generated the indicated GST-IKK-a (335-745) mutants where Ser was substituted to Ala (Figure 4c ). Unfortunately, Escherichia coli did not express IKK-a (T659A). Each of these GST fusion proteins except IKK-a (T659A) was incubated with anti-ATM immunoprecipitates prepared from CDDP-treated HeLa cells in the presence of [g-32 P]ATP. Reaction mixtures were then separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis followed by autoradiography. As shown in Figure 4c , anti-ATM immunoprecipitates phosphorylated IKK-a (S351A), IKK-a (S369A) and IKK-a (S596A). In contrast, IKK-a (S473A) was labeled to a lesser degree. Collectively, our results suggest that ATM phosphorylates IKK-a at Ser-473 in response to CDDP.
We then asked whether IKK-a could affect CDDP sensitivity. At the indicated time points after CDDP treatment, cell viability of wild-type MEFs and MEFs from IKK-a knockout mice (Begg et al., 1995) was examined by MTT assay. As shown in left panel of Figure 4d , IKK-a-deficient MEFs displayed CDDPresistant phenotype relative to wild-type MEFs, suggesting that IKK-a plays a critical role in the regulation of DNA damage response. Immunoblot analysis demonstrated that CDDP-mediated phosphorylation of ATM is detectable in both MEFs (right panel of Figure 4d ). Consistent with our recent observations (Furuya et al., 2007) , CDDP-mediated accumulation of IKK-a and p73a was detectable in wild-type MEFs. In contrast, p73a remained constant in IKK-a-deficient MEFs exposed to CDDP. Thus, it is likely that ATM transmits apoptotic signal through nuclear IKK-a, and thereby promotes the stabilization of pro-apoptotic p73.
Our results indicated that Ser-473 of IKK-a is at least one of the potential targets of ATM-mediated phosphorylation in response to CDDP. Accumulating evidence suggests that the activation of IKK complex is dependent on its phosphorylation (Hayden and Ghosh, 2004) . Delhase et al. (1999) described that IKK-b is autophosphorylated at its C-terminal region to regulate its activity. Alternatively, NF-kBinducing kinase (NIK) directly phosphorylates and activates IKK-a (Regnier et al., 1997) . Intriguingly, Li et al. (2001) reported that ATM is required for DNA damage-induced activation of IKK-a, which supports our present results. Another finding of our present study is that CDDP-mediated nuclear accumulation of IKK-a is regulated in an ubiquitin/proteasome-dependent manner. In response to DNA damage, p53 is phosphorylated at its N-terminal region, which blocks MDM2-mediated ubiquitination of p53 (Vousden and Lu, 2002) , raising a possibility that ATM-mediated phosphorylation of IKK-a might inhibit its ubiquitination and subsequent degradation through ubiquitin/ proteasome pathway. Further work should be necessary to resolve this issue. Nuclear IKK-a is regulated in a proteasome-dependent manner. U2OS cells were treated with 50 mM of MG-132 for 6 h and then fractionated into nuclear and cytoplasmic fractions followed by IB with the indicated antibodies. (c) CDDPinduced reduction in ubiquitination levels of IKK-a. Expression plasmid for IKK-a was introduced into U2OS cells along with Hisubiquitin (His-Ub) and treated with or without CDDP at the indicated concentrations. Ubiquitinated materials were recovered by nickel agarose (Qiagen, Valencia, CA, USA) and separated by SDS-PAGE followed by IB with anti-IKK-a antibody.
